Advanced Prostate Cancer VL

Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh

Details
Ali Sabbagh presents a novel study on using machine learning to predict overall survival in clinical trials for metastatic prostate cancer. Dr. Sabbagh explains that traditional endpoints like overall survival often require long follow-ups, delaying access to potentially life-saving treatments. His research leverages baseline clinical characteristics and PSA changes over four months to accelerate...

ARAMIS Trial: Deep PSA Responses with Darolutamide Linked to Minimal Radiographic Progression - Alicia Morgans

Details
Zach Klaassen and Alicia Morgans discuss the findings from an exploratory analysis of the ARAMIS trial, focusing on the efficacy of darolutamide for non-metastatic castration-resistant prostate cancer (nmCRPC). Dr. Morgans explains that darolutamide, approved after the ARAMIS phase 3 trial, significantly improves metastasis-free survival by 22 months and reduces mortality by 31% compared to placeb...

Navigating the Landscape of FDA-Approved PSMA Diagnostics: Pros and Cons - Delphine Chen

Details
Delphine Chen discusses the evolving landscape of PSMA diagnostics and therapies for prostate cancer with Phillip Koo. Dr. Chen outlines the use and performance of key PSMA imaging agents: Gallium-68 PSMA-11, and the F-18 agents PYLARIFY and POSLUMA. She explains how Gallium-68 PSMA-11, traditionally paired with Lutetium-177 PSMA, is effective but newer F-18 agents offer higher signal-to-noise rat...

Dose-Escalation of Lutetium PSMA: Final Results from a Phase I/II Trial - Scott Tagawa

Details
Scott Tagawa discusses the final results of a phase I/II trial exploring dose-escalation of lutetium PSMA for advanced prostate cancer. Launched in 2017, this trial aimed to determine the safety and efficacy of increasing radioactive doses in a fractionated, dose-dense regimen to maintain constant tumor exposure. The study escalated doses from 7.4 to 22.2 gigabecquerels without reaching a dose-lim...

Exploring Genetic Counseling in Veterans with Advanced Prostate Cancer - Daniel Kwon

Details
Daniel Kwon presents a study on genetic counseling for Veterans with advanced prostate cancer. This mixed-methods research combines in-depth qualitative interviews and quantitative surveys to evaluate how well Veterans understand and make decisions about genetic testing. Initial interviews with 31 patients reveal that most found the decision straightforward, but some had uncertainties about the im...

OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan

Details
Zach Klaassen and Benjamin Maughan discuss new insights into the real-world application of apalutamide in treating metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Maughan highlights the significance of achieving deep PSA responses as a key prognostic marker for patient outcomes. The OASIS project, utilizing data from diverse medical settings across the U.S., demonstrates that patients wh...

ARV-766: Efficacy and Safety of a Second-Generation AR Degrader in Prostate Cancer - Daniel Petrylak

Details
Alicia Morgans speaks with Dan Petrylak about his phase 1 study on a new androgen receptor (AR) degrader, ARV-766. This study explores the potential of AR degraders to effectively target and dismantle androgen receptors in prostate cancer cells, particularly those resistant to conventional therapies. Dr. Petrylak highlights the journey of ARV-766, a second-generation PROTAC drug designed to degrad...

CHAARTED 2 Study Shows PFS Benefit with Cabazitaxel in Metastatic Prostate Cancer in Phase 2 - Christos Kyriakopoulos

Details
Alicia Morgans sits down with Christos Kyriakopoulos to discuss the findings from the CHAARTED 2 trial. This study builds on the success of the original CHAARTED trial, focusing on combining standard therapies with second-line chemotherapy to improve outcomes for patients with metastatic castration-resistant prostate cancer. Initiated in 2018 and completed amid the challenges of the COVID-19 pande...

Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi

Details
Susan Halabi discusses her presentation on prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) based on the Alliance trial. The phase three trial, which enrolled 1,311 patients, compared the effects of enzalutamide alone to enzalutamide combined with abiraterone and prednisone. Despite no difference in overall survival between the treatment arms, Dr. Halabi's team develop...

PROMISE Criteria: Enhanced Survival Prediction in Prostate Cancer with PSMA PET - Wolfgang Fendler

Details
Phillip Koo interviews Wolfgang Fendler about advancements in PSMA PET imaging and its prognostic capabilities. Dr. Fendler highlights that the PROMISE criteria, developed for standardized PSMA PET reporting, now show significant prognostic value in predicting overall survival in prostate cancer across all stages. His team’s research demonstrates that metrics like total tumor volume and average PS...